Camille L. Bedrosian

Chief Medical Officer, Amylyx Pharmaceuticals

Appears in 1 story

Stories

Amylyx Phase III success for avexitide sets up FDA filing

Leading avexitide clinical development

Post-bariatric hypoglycemia has no FDA-approved treatment. Amylyx Pharmaceuticals just moved to change that: its Phase III LUCIDITY trial showed avexitide cut dangerous hypoglycemic events by 55% versus placebo (p=0.000003), and the company plans to file for FDA approval by year-end.

Updated Yesterday